← SynDRA
ZAPRINAST
SynDRA canonical compound SYN0001694 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PDE5A |
|---|
| Mechanism of action | Phosphodiesterase inhibitor |
|---|
All known targets
- PDE5A
- GPR35
- PDE9A
- MPC1L
- MPC2
- PDE1A
- PDE4D
Mechanisms of action (all sources)
- Phosphodiesterase inhibitor
- GPR35 AGONIST
- MPC1L INHIBITOR
- MPC2 INHIBITOR
- PDE5A INHIBITOR
- PDE9A INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE1C
- ABCC10
- MAOA
- NPY2R
- NPY1R
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPT
- MAPK3
- MAPK14
- MAPK1
- LMNA
- OPRD1
- LCK
- KDM4E
- KCNH2
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HRH3
- HRH2
- HRH1
- HPGD
- HMGCR
- NR3C1
- OPRK1
- GMNN
- OPRM1
- USP2
- TDP1
- TBXAS1
- TACR2
- TACR1
- SLCO1B3
- SLCO1B1
- SLC6A4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP1A2
- LOX15
- PDE1B
- PDE6A
- PDE6B
- PDE6C
- PDE6D
- PDE6G
- PDE6H
- PHGDH
- UBP2
Drug classes
- Phosphodiesterase Inhibitors
Cross-references
Synonyms
- M&B-22948
- NSC-757885
- Zaprinastum
- NSC 757885
- GXT25D5DS0
- 2-o-Propoxyphenyl-8-azapurine-6-one
- DTXCID6025224
- 2-(2-propoxyphenyl)-8-azapurin-6-one
- RefChem:904807
- Tocris-0947
- NCGC00016105-03
- CAS-37762-06-4
- 2-(o-Propoxyphenyl)-8-azapurin-6-one
- Zaprinastum [INN-Latin]
- M&B 22,948
- M and B 22948
- 8-Aza-2-(2-propoxyphenyl)-6-purinone
- Zaprinast [INN:BAN]
- SR-01000075536
- EINECS 253-655-1
- UNII-GXT25D5DS0
- Zaprinast?
- Zaprinast, solid
- Prestwick_655
- 2-o-Propoxyphenyl-8-azapurin-6-on
- MFCD00214073
- Spectrum_001265
- ZAPRINAST [INN]
- Prestwick0_000335
- Prestwick1_000335
- Prestwick2_000335
- Prestwick3_000335
- Spectrum2_001447
- Spectrum3_000933
- Spectrum4_001032
- Spectrum5_001023
- Lopac-Z-0878
- ZAPRINAST [MART.]
Look up ZAPRINAST in the interactive SynDRA portal →